LINC01192: A Non-Protein-Coding RNA Molecule with Potential as A Cancer Drug Target

Target Name: LINC01192

NCBI ID: G647107

LINC01192

Other Name(s): Cancer/testis antigen 64 (non-protein coding) | long intergenic non-protein coding RNA 1192 | CT64 | Long intergenic non-protein coding RNA 1192

LINC01192: A Non-Protein-Coding RNA Molecule with Potential as A Cancer Drug Target

LINC01192 is a non-protein coding RNA molecule that is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. It is also known as cancer/testis antigen 64 (CTAn64) and has been identified as a potential drug target in the field of cancer.

LINC01192 is a small non-coding RNA molecule that is approximately 200 nucleotides in length. It is expressed in a variety of tissues and organs, including the brain, heart, and gastrointestinal tract. It is also expressed in the placenta and has been shown to be present in the bloodstream.

One of the unique features of LINC01192 is its expression pattern. It is mainly expressed in the brain and has been shown to be present in the chocolate and blood. Its expression pattern is also affected by a variety of regulatory factors, including DNA methylation, RNA-binding proteins, etc.

LINC01192 has also been shown to play a role in several cellular processes, including cell signaling, cell adhesion, and cell survival. It has been shown to interact with several protein molecules, including FAK, PDGF, and NF-kappa-B.

Furthermore, LINC01192 has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, LINC01192 has been shown to be overexpressed in several types of cancer, including breast cancer, lung cancer, and colon cancer. It has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition, LINC01192 has also been shown to be involved in several autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis.

Despite its potential as a drug target, LINC01192 has not yet been studied extensively, and more research is needed to fully understand its role in disease.

Protein Name: Long Intergenic Non-protein Coding RNA 1192

The "LINC01192 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01192 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets